BR0110779A - Composições e métodos para adquirir supressão imunológica - Google Patents

Composições e métodos para adquirir supressão imunológica

Info

Publication number
BR0110779A
BR0110779A BR0110779-8A BR0110779A BR0110779A BR 0110779 A BR0110779 A BR 0110779A BR 0110779 A BR0110779 A BR 0110779A BR 0110779 A BR0110779 A BR 0110779A
Authority
BR
Brazil
Prior art keywords
compositions
methods
immune suppression
acquiring
agent
Prior art date
Application number
BR0110779-8A
Other languages
English (en)
Inventor
Terry B Strom
Wlodzimierz Maslinski
Xin Xiao Zheng
Yon Su Kim
Sylvie Ferrari Lacraz
Original Assignee
Beth Israel Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beth Israel Hospital filed Critical Beth Israel Hospital
Publication of BR0110779A publication Critical patent/BR0110779A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5443—IL-15

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)

Abstract

"COMPOSIçõES E MéTODOS PARA ADQUIRIR SUPRESSãO IMUNOLóGICA". Composição que compreende um primeiro agente que direciona um receptor de interleucina-15 (IL-15R) e um segundo agente que inibe um sinal co-estimulador transmitido entre uma célula T e uma célula que apresenta antígeno (APC). A dita composição pode ser usada para o diagnóstico e a terapia de doenças imunes, especialmente doenças auto-imunes.
BR0110779-8A 2000-05-12 2001-05-14 Composições e métodos para adquirir supressão imunológica BR0110779A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20380100P 2000-05-12 2000-05-12
PCT/US2001/015578 WO2001087330A2 (en) 2000-05-12 2001-05-14 Compositions and methods for achieving immune suppression

Publications (1)

Publication Number Publication Date
BR0110779A true BR0110779A (pt) 2005-01-11

Family

ID=22755375

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0110779-8A BR0110779A (pt) 2000-05-12 2001-05-14 Composições e métodos para adquirir supressão imunológica

Country Status (9)

Country Link
US (2) US6797263B2 (pt)
EP (1) EP1284747A2 (pt)
JP (1) JP2003533488A (pt)
CN (1) CN1441675A (pt)
AU (2) AU2001261585B2 (pt)
BR (1) BR0110779A (pt)
CA (1) CA2408691A1 (pt)
RU (1) RU2270691C2 (pt)
WO (1) WO2001087330A2 (pt)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6905827B2 (en) 2001-06-08 2005-06-14 Expression Diagnostics, Inc. Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases
US7026121B1 (en) 2001-06-08 2006-04-11 Expression Diagnostics, Inc. Methods and compositions for diagnosing and monitoring transplant rejection
US7235358B2 (en) 2001-06-08 2007-06-26 Expression Diagnostics, Inc. Methods and compositions for diagnosing and monitoring transplant rejection
CN1705744A (zh) * 2002-10-14 2005-12-07 豪夫迈－罗氏公司 具有免疫调节剂的可移植细胞
US7892745B2 (en) 2003-04-24 2011-02-22 Xdx, Inc. Methods and compositions for diagnosing and monitoring transplant rejection
KR20050082389A (ko) * 2004-02-18 2005-08-23 메덱스젠 주식회사 직렬 연쇄체를 갖는 면역접합체를 포함하는 장기이식합병증 치료용 약제학적 조성물
CA2562766A1 (en) * 2004-04-14 2005-10-27 F. Hoffmann-La Roche Ag Purified interleukin-15/fc fusion protein and preparation thereof
WO2006029184A2 (en) * 2004-09-08 2006-03-16 Expression Diagnostics, Inc. Genes useful for diagnosing and monitoring inflammation related disorders
WO2006124827A2 (en) * 2005-05-13 2006-11-23 University Of Miami Molecular dissection of cellular responses to alloantigen or autoantigen in graft rejection and autoimmune disease
EP1901773B1 (en) * 2005-06-09 2012-03-07 Hansa Medical AB Use of the ides proteinase (from s. pyogenes) for treating autoimmune diseases and graft rejection
JP5709356B2 (ja) 2006-01-13 2015-04-30 アメリカ合衆国 哺乳動物細胞における発現のためのコドン最適化ＩＬ−１５およびＩＬ−１５Ｒ−α遺伝子
WO2008021431A2 (en) 2006-08-14 2008-02-21 Xdx, Inc. Methods and compositions for diagnosing and monitoring the status of transplant rejection and immune disorders
EP2102367A2 (en) 2006-11-09 2009-09-23 XDX, Inc. Methods for diagnosing and monitoring the status of systemic lupus erythematosus
CA3028038C (en) 2007-05-11 2021-08-10 Altor Bioscience Corporation Fusion molecules and il-15 variants
AU2010282280B2 (en) 2009-08-14 2016-06-09 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of IL-15 to increase thymic output and to treat lymphopenia
PT2619229T (pt) 2010-09-21 2016-07-13 Altor Bioscience Corp Moléculas de fusão de il-15 multiméricas solúveis e métodos de produção e utilização das mesmas
US11053299B2 (en) 2010-09-21 2021-07-06 Immunity Bio, Inc. Superkine
WO2015089217A2 (en) 2013-12-10 2015-06-18 Bionz, Llc Methods of developing selective peptide antagonists
EP3636274A1 (en) 2011-01-18 2020-04-15 Bioniz, LLC Compositions and methods for modulating gamma-c-cytokine activity
EP2915569A1 (en) 2014-03-03 2015-09-09 Cytune Pharma IL-15/IL-15Ralpha based conjugates purification method
KR20230028807A (ko) 2014-06-30 2023-03-02 알토 바이오사이언스 코포레이션 Il-15-베이즈드 분자 및 이의 사용 방법
MA41459A (fr) * 2015-02-03 2017-12-12 Als Therapy Development Inst Anticorps anti-cd40l et méthodes pour traiter des maladies ou des troubles liés aux cd40l
PL3359556T3 (pl) 2015-10-09 2021-11-22 Bioniz, Llc Modulowanie aktywności gamma-c-cytokin
BR112019007920A2 (pt) 2016-10-21 2019-10-08 Altor Bioscience Corp moléculas multiméricas à base de il-15
US11344578B2 (en) 2017-04-19 2022-05-31 Board Of Regents, The University Of Texas System Immune cells expressing engineered antigen receptors
AU2018271915A1 (en) 2017-05-24 2019-11-28 Als Therapy Development Institute Therapeutic anti-CD40 ligand antibodies
CN107474143B (zh) * 2017-09-13 2020-08-11 深圳市因诺赛生物科技有限公司 (Anti-CD40 mAb)-CTLA4融合蛋白及其用途
MX2022002747A (es) 2019-09-10 2022-04-06 Obsidian Therapeutics Inc Proteinas de fusion de ca2-il15 para regulacion ajustable.

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
ES2198025T3 (es) 1991-10-25 2004-01-16 Immunex Corporation Anticuerpos contra cd40-l.
GB9207732D0 (en) 1992-04-06 1992-05-27 Isis Innovation Wound repair
JP3494647B2 (ja) 1992-08-20 2004-02-09 シェリング・コーポレーション Ｉｌ−４および／またはｉｌ−１０ならびにそれらに対する抗体の新規な用途
AU5098493A (en) 1992-08-21 1994-03-15 Schering Corporation Cd40 ligand, anti cd40 antibodies, and soluble cd40
EP0681589A1 (en) 1993-02-01 1995-11-15 Université Libre de Bruxelles Use of a pharmaceutical composition comprising an effective amount of interleukin-10, an analog and/or an agonist of interleukin-10
US5574138A (en) 1993-03-08 1996-11-12 Immunex Corporation Epithelium-derived T-cell factor
US5747024A (en) 1993-03-08 1998-05-05 Immunex Corporation Vaccine adjuvant comprising interleukin-15
US5552303A (en) 1993-03-08 1996-09-03 Immunex Corporation DNA encoding epithelium-derived T-cell factor
IL110852A (en) 1993-09-02 1999-05-09 Dartmouth College Methods of prolonged suppression of humoral activity
CN1127351C (zh) 1993-09-02 2003-11-12 达特茅斯学院理事 诱导抗原特异性ｔ细胞耐受的方法
DK0772624T3 (da) 1994-04-06 2000-11-13 Immunex Corp Interleukin-15
US5683693A (en) 1994-04-25 1997-11-04 Trustees Of Dartmouth College Method for inducing T cell unresponsiveness to a tissue or organ graft with anti-CD40 ligand antibody or soluble CD40
US6265556B1 (en) 1994-12-02 2001-07-24 The Burnham Institute Nucleic acid encoding CD40 associated proteins
US5876950A (en) 1995-01-26 1999-03-02 Bristol-Myers Squibb Company Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy
US5795966A (en) 1995-02-22 1998-08-18 Immunex Corp Antagonists of interleukin-15
US5833987A (en) 1995-06-07 1998-11-10 Trustees Of Dartmouth College Treatment of T cell mediated autoimmune disorders
US6440418B1 (en) 1995-11-07 2002-08-27 Idec Pharmaceuticals Corporation Methods of treating autoimmune diseases with gp39-specific antibodies
US6001358A (en) 1995-11-07 1999-12-14 Idec Pharmaceuticals Corporation Humanized antibodies to human gp39, compositions containing thereof
US6340459B1 (en) 1995-12-01 2002-01-22 The Trustees Of Columbia University In The City Of New York Therapeutic applications for the anti-T-BAM (CD40-L) monoclonal antibody 5C8 in the treatment of reperfusion injury in non-transplant recipients
US6132978A (en) 1995-12-19 2000-10-17 National Jewish Medical And Research Center Method to regulate CD40 signaling
EP0874637A1 (en) 1996-01-16 1998-11-04 The Trustees of Columbia University in the City of New York Therapeutic applications of t-bam (cd40l) technology to treat inflammatory kidney diseases
DK0892643T4 (da) 1996-03-20 2009-12-14 Bristol Myers Squibb Co Fremgangsmåder til inhibering af et immunrespons ved blokering af GP39/CD40- og CTLA4/CD28/B7-banerne og præparater til anvendelse derved
DE69733610T2 (de) * 1996-04-26 2006-05-11 Beth Israel Deaconess Medical Center, Inc., Boston Interleukin-15 antagonisten
BR9710264A (pt) 1996-07-08 1999-08-10 Univ Columbia Aplicações terapéuticas da tecnologia do t-bam (cd40l) para tratar de doenças envolvendo as células do músculo liso
DE19823351A1 (de) * 1997-05-16 1998-12-10 Krause Hans Mittel zur Verhinderung der Zellapoptose bei Krankheiten
CA2291156A1 (en) 1997-05-17 1998-11-26 Biogen, Inc. Use of a cd40:cd154 binding interruptor to prevent counter adaptive immune responses, particularly graft rejection
AU748533B2 (en) 1997-06-11 2002-06-06 United States Of America As Represented By The Secretary Of The Navy, The Composition and method to prevent graft rejection and other counter-adaptive T lymphocyte mediated immune responses
NZ502051A (en) 1997-06-20 2001-04-27 Biogen Inc CD154 blockade therapy for therapeutic protein inhibitor syndrome
WO1999000143A1 (en) 1997-06-27 1999-01-07 Biogen, Inc. Cd154 blockade therapy for autoimmune diseases

Also Published As

Publication number Publication date
RU2270691C2 (ru) 2006-02-27
US20040219148A1 (en) 2004-11-04
WO2001087330A2 (en) 2001-11-22
US6797263B2 (en) 2004-09-28
EP1284747A2 (en) 2003-02-26
CA2408691A1 (en) 2001-11-22
WO2001087330A3 (en) 2002-05-30
CN1441675A (zh) 2003-09-10
AU2001261585C1 (en) 2001-11-26
US20020128436A1 (en) 2002-09-12
US7347995B2 (en) 2008-03-25
AU6158501A (en) 2001-11-26
JP2003533488A (ja) 2003-11-11
AU2001261585B2 (en) 2006-08-31

Similar Documents

Publication Publication Date Title
BR0110779A (pt) Composições e métodos para adquirir supressão imunológica
PE20020968A1 (es) Preparados de insulina exentos de zinc y pobres en zinc, con estabilidad mejorada
MA30023B1 (fr) Nouvelle composition
Tonetti et al. Compartmentalization of inflammatory cell phenotypes in normal gingiva and peri‐implant keratinized mucosa
BR0113906A (pt) Modulação de respostas de células t mediadas por il-2 e il-15
ATE196314T1 (de) Verfahren und zusammensetzungen zur verhinderung von entzündungen und angiogenese enthaltend säugetieren cd97 alpha untereinheit
CA2103443A1 (en) Chewable Drug-Delivery Composition
CO5560558A2 (es) Uso de una composicion de celecoxib para rapido alivio del dolor
AR013499A1 (es) Composiciones solidas que comprenden un polipeptido ciclosporina y un surfactante anionico
BR9909915A (pt) Composições adjuvantes
FI953442A (fi) Gonadotropiinia sisältäviä pakastekuivattuja pallosia
DE69105106T2 (de) Im wasser schnell suspendierbare pharmazeutische zusammensetzung.
CY1111863T1 (el) Αντισωματα εναντιον υποδοχεα θανατου 4 (dr4) και χρησεις αυτων
CO5670348A2 (es) Sistema hidrofobo para blanquear los dientes y metodos de uso
FI974423A (fi) Immunologiset yhdistelmäkoostumukset ja menetelmät
DE69715259D1 (de) Infektionsfreie intramammäre tierarzneimittelzusammenstellung
DE69518237D1 (de) Feste pharmazeutische zubereitung mit (s)-2-(4-isobutylphenyl)propionsäure als wirkstoff und mikrokristalliner cellulose und kolloidalem silica als hilfstoff
PT745388E (pt) Composicao de vacinas para mamiferos compreendendo esqualeno ou esqualano fosfolipido e um tensioactivo como adjevante
Dimitriadou et al. Expression of functional major histocompatility complex class II molecules on HMC‐1 human mast cells
DE69617395T2 (de) Pharmazeutische zusammensetzungen enthaltent ein superoxyddismutase
EE05213B1 (et) Lmfotoksiin- β retseptori (LT- β-R) blokeeriva agensi kasutamine ja LT- β-R-i blokeerivat agensit ning CD40L-i blokeerivat agensit sisaldav farmatseutiline kompositsioon
AU7635396A (en) Treatment and diagnosis of infections due to helicobacter pylori
GEP20053446B (en) Adjuvant Combination Formulations
Vanclee et al. Keratinocyte growth factor ameliorates acute graft-versus-host disease in a novel nonmyeloablative haploidentical transplantation model
Annessi et al. Multinucleate cell angiohistiocytoma

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A,9A E 10A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2144 DE 07/02/2012.